Not provided
Not provided
Not provided
Not provided
Not provided
Lack of funding
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary purpose of this study is to investigate the safety and efficacy of bilateral DWT in subjects with POAG or OHT compared to active and sham controls. The secondary purpose of the study is to investigate the durability, repeatability, and does response of the same.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| DWT device dose A | Experimental | Deep Wave Trabeculoplasty (DWT) dose A (10 second spot treatments). |
|
| Ellex Tango SLT machine | Active Comparator | Selective Laser Trabeculoplasty (SLT) |
|
| DWT Sham | Sham Comparator | Deep Wave Trabeculoplasty (DWT) but device not applied to ocular surface. |
|
| DWT device dose B | Experimental | Deep Wave Trabeculoplasty (DWT) dose B (20 second spot treatments). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| DWT device dose A | Device | Deep Wave Trabeculoplasty (DWT) is an investigational device intended to reduce IOP in patients with POAG or OHT. The DWT device applies focal mechanical oscillation (low amplitude, sonic frequency) to the surface of the eye proximate the limbal region and anterior to the trabecular meshwork (TM). Mechanical oscillation of the TM by the DWT device is believed to initiate a physiological cascade to restore function of the TM, increase the outflow of aqueous humor and thereby decrease the IOP. DWT involves 24 spot treatments applied around the limbal region on the ocular surface. Dose A refers to 10 second spot treatments. |
| Measure | Description | Time Frame |
|---|---|---|
| Percent decrease in IOP and change in dependence on IOP-lowering medications from baseline | 6 months | |
| Intra-procedural and post-procedural adverse events | 6 months |
Not provided
Not provided
Inclusion Criteria:
Male or female subjects, 18 years or older.
Subjects diagnosed with either POAG or OHT in both eyes. The diagnosis of POAG must include evidence of:
Subjects with a 9:00AM (+/- 1 hour) median IOP in both eyes that is:
Subjects currently using one or more topical medications to control their IOP.
Subjects able and willing to comply with the protocol, including randomization assignment and all follow-up visits.
Subjects that sign the informed consent form.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Harvey Siy Uy, MD | Pacific Eye and Laser Institute | Principal Investigator |
| Edgar U. Leuenberger, MD | Asian Eye Institute | Principal Investigator |
| Maria I Yap-Veloso, MD | Asian Eye Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Asian Eye Institute | Makati City | Philippines | ||||
| Pacific Eye and Laser Institute |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Ellex Tango SLT machine | Device | Laser trabeculoplasty is the application of a laser beam to burn areas of the trabecular meshwork, located near the base of the iris, to increase fluid outflow. Selective laser trabeculoplasty (SLT) uses a Nd:YAG laser to target specific cells within the trabecular meshwork and create thermal damage. |
|
| DWT device dose B | Device | Same as DWT device dose A except 20 second spot treatments. |
|
| DWT sham | Device | Same as DWT device dose A except device not applied to ocular surface. |
|
| Makati City |
| Philippines |
| ID | Term |
|---|---|
| D005902 | Glaucoma, Open-Angle |
| D009798 | Ocular Hypertension |
| D005901 | Glaucoma |
| ID | Term |
|---|---|
| D005128 | Eye Diseases |
Not provided
Not provided